New hope for liver cancer: Triple-Drug combo trial launches
NCT ID NCT07219459
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2b trial tests whether adding visugromab and nivolumab to standard lenvatinib can help people with advanced liver cancer that has worsened after initial treatment. About 104 participants will receive either the triple combination or a placebo plus lenvatinib. The study aims to see if the new combo slows cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
visugromab (CTL-002) combined with nivolumab and lenvatinib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer who have stopped responding to initial therapy.
What could go wrong
This is a mid-stage trial with only 104 participants, so results may not apply to everyone. The added drugs may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asst Grande Ospedale Metropolitano Niguarda
RECRUITINGMilan, 20162, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hannover Medical School
RECRUITINGHanover, Lower Saxony, 30625, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clinic of Barcelona
RECRUITINGBarcelona, Catalonia, 08036, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
OSF St. Francis Medical Center
RECRUITINGPeoria, Illinois, 61637, United States
Contact Email: •••••@•••••
-
Peidmont Healthcare, Inc
RECRUITINGAtlanta, Georgia, 30309, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Polyclinic S. Orsola-Malpighi
RECRUITINGBologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Clinic of Navarra - Pamplona
RECRUITINGPamplona, Chartered Community of Navarra, 31008, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Miguel Servet
RECRUITINGZaragoza, Aragon, 50009, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Hospital Ramon y Cajal
RECRUITINGMadrid, Madrid, 28034, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Medical Center of Johannes Gutenberg University Mainz
RECRUITINGMainz, Rhineland-Palatinate, 55131, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Frankfurt Johann Wolfgang Goethe- Universität
RECRUITINGFrankfurt, 60590, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••